| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $13.3M | -13.8% |
| SG&A Expense | $15.4M | +52.6% |
| Operating Income | -$28.7M | -12.5% |
| Pre-tax Income | -$28.7M | -26.3% |
| Income Tax | $79K | -16.8% |
| Net Income | -$28.8M | -26.2% |
| EPS (Basic) | -$0.30 | +0.0% |
| EPS (Diluted) | -$0.30 | +0.0% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $5.2M | -53.0% |
| Current Assets | $6.8M | -45.0% |
| Total Assets | $7.6M | -43.5% |
| Current Liabilities | $6.1M | +24.9% |
| Total Liabilities | $11.4M | +12.4% |
| Stockholders' Equity | -$3.8M | -215.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$20.1M | -1.2% |
| Capital Expenditures | $6K | -96.6% |
| Investing Cash Flow | -$6K | +96.6% |
| Financing Cash Flow | $14.1M | +180.8% |
| Free Cash Flow | -$20.1M | -0.3% |